We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Geron Corp (GERN) Worth a Look: Stock Adds 7% in Session
Geron Corporation (GERN - Free Report) was a big mover last session, as the company saw its shares rise over 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock is now up over 22% in the past one-month time frame.
The company has seen one positive estimate revision in the last 30 days, while the Zacks Consensus Estimate remained unchanged. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Currently, Geron Corporation carries a Zacks Rank #2 (Buy).
Geron Corporation Price
Geron Corporation Price | Geron Corporation Quote
Another top-ranked stock in the same industry is Akari Therapeutics, Plc (AKTX - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is GERN going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course. Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>